logo
RFK Jr's new vaccine panel votes against preservative in flu shots in shock move

RFK Jr's new vaccine panel votes against preservative in flu shots in shock move

Yahoo13 hours ago

A critical federal vaccine panel has recommended against seasonal influenza vaccines containing a specific preservative – a change likely to send shock through the global medical and scientific community and possibly impact future vaccine availability.
The panel was unilaterally remade by health secretary Robert F Kennedy Jr, a vaccine skeptic who has urged against the use of thimerosal despite a lack of evidence of real-world harm.
Across three votes, members voted in favor of restricting thimerosal in seasonal influenza vaccines across all age groups – with five in favor of the restriction, one abstention and one vote against.
'The risk from influenza is so much greater than the nonexistent – as far as we know – risk from thimerosal,' said Dr Cody Meissner, a panel member and professor of pediatrics at Dartmouth's Geisel School of Medicine who was the lone 'no' vote.
'I would hate for a person not to receive the influenza vaccine because the only availability preparation contains thimerosal – I find that very hard to justify.'
The panel, formally called the Advisory Committee for Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), is a critical link in the vaccine distribution pipeline – informing health insurers and clinicians alike about which vaccines to give patients.
Kennedy fired all 17 former members of the panel in June, citing conflicts of interest, and appointed eight new members, all of whom are ideological allies of the secretary.
None of the new members have published written conflict of interest disclosures or been added to a Trump administration-developed conflict of interest tracker for ACIP members, as of Thursday morning.
'There is a very big difference between what was shared at the meeting versus what is reality,' said Dr Sean O'Leary, chair of the American Academy of Pediatrics Committee on Infectious Diseases. 'The science on thimerosal is settled, and the rhetoric being used to suggest otherwise is misleading and harmful.'
Rather than vote on an agenda that had once included seasonal recommendations for Covid-19 and the vaccine against human papilloma virus (HPV), ACIP added the controversial focus of thimerosal in vaccines. The panel affirmed that the influenza vaccine is recommended for Americans older than six months.
Related: RFK Jr will be 'personally responsible' for children's deaths by halting vaccine alliance funding, experts say
Although multiple studies have found no real-world harm, the preservative has been a talking point of anti-vaccine advocates for decades. Multiple representatives of physicians associations urged the panel to reject the recommendation against thimerosal in the meeting.
Thimerosal is used in about 5% of multidose seasonal influenza vials, and is known to be more cost effective than single-dose formulations. It is unclear how the vote will impact flu vaccine availability before the upcoming flu season, particularly for clinics that rely on such formulations.
Thimerosal has been used as a preservative in vaccines since before the second world war. In the early 2000s, thimerosal was removed from all routine pediatric and most adult vaccines as a precautionary measure – a decision that was criticized by experts who argued it sent mixed messages about a preservative that had not been found to cause harm. The issue has since been considered settled by mainstream medicine.
Thimerosal is an ethylmercury-based preservative. Ethylmercury is different from the kind of mercury found in seafood, called methylmercury. Ethylmercury has a much shorter half-life in the blood and brain, about seven days and 30 days respectively, compared to methylmercury, which has an approximately 44-58 day half-life and accumulates in the brain. The amount of ethylmercury contained in a flu vaccine (25 micrograms) is about half of that contained in a 3-ounce serving of canned tuna fish (40 micrograms).
Repeated, large studies conducted across several countries have found no association between thimerosal and neurological effects. A presentation from CDC career scientists that was initially expected to go through some of this substantial data was removed before the panel reconvened on Thursday.
In response to a question about the slapped down presentation, ACIP member Dr Robert Malone, a well-known anti-vaccine activist, said: 'That article was not authorized by the office of the secretary and was removed.'
The panel instead heard a presentation from Lyn Redwood, a nurse practitioner who founded the World Mercury Project, the predecessor to Kennedy's anti-vaccine advocacy group Children's Health Defense. Prior to the meeting, her presentation was found to include a reference to a study that appeared to be made up.
'This is an old issue that has been addressed in the past and there are many issues we could discuss,' said Meissner.
The best public interest journalism relies on first-hand accounts from people in the know.
If you have something to share on this subject you can contact us confidentially using the following methods.
Secure Messaging in the Guardian app
The Guardian app has a tool to send tips about stories. Messages are end to end encrypted and concealed within the routine activity that every Guardian mobile app performs. This prevents an observer from knowing that you are communicating with us at all, let alone what is being said.
If you don't already have the Guardian app, download it (iOS/Android) and go to the menu. Select 'Secure Messaging'.
SecureDrop, instant messengers, email, telephone and post
See our guide at theguardian.com/tips for alternative methods and the pros and cons of each.
Responding to criticism of Redwood's presentation, ACIP chair Dr Martin Kulldorff, a former Harvard professor who was fired for refusing the Covid-19 vaccine, said: 'It's inappropriate to dismiss a presentation just because the person does not have a PhD or MD.'
The decision from ACIP could have global implications, because vaccines used around the world rely on thimerosal as a preservative in multidose vials, which are less expensive.
'I know ACIP is focused on the US, but recommendations that the ACIP makes are followed among many countries around the world,' said Meissner.
'Removing thimerosal from all vaccines used in other countries, for example, is going to reduce access to these vaccines, it will increase costs, and I think it's important to note that no study has ever indicated any harm from thimerosal.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes
Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes

Yahoo

time34 minutes ago

  • Yahoo

Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes

Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes originally appeared on Parade. There's nothing quite like a crisp diet soda on a hot day. It's cool, bubbly and somehow so refreshing. Add some lime and you've got a summertime treat. You can even make a dirty soda by adding a little cream. Yum! But a new study is shining light on diet soda's health effects, and they might not be as harmless as they seem. A new study has found that consuming artificially sweetened beverages, which are commonly marketed as the 'healthier' alternative to sugary drinks, could significantly increase your risk of developing type 2 diabetes. Researchers collected data on more than 4,654 adults in the 30-year-long Coronary Artery Risk Development in Young Adults (CARDIA) study. They assessed the diets of participants at the start of the study, then again after seven and 20 years. 🎬 SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox 🎬 Researchers discovered that individuals who consumed the highest amounts of artificially sweetened drinks, like diet sodas or sugar-free flavored waters, were more than twice as likely to develop type 2 diabetes than those who rarely drank them. That's a 129% increase in risk, raising serious questions about what we're really sipping on when we go 'sugar-free.'The study adds fuel to the growing debate around artificial sweeteners. Long considered a safer option for those watching their weight or blood sugar, these sugar substitutes may interfere with insulin sensitivity and disrupt gut health, which are two key factors in developing diabetes. While the beverages contain few or no calories, their long-term metabolic effects may not be so benign. Of course, sugary drinks aren't off the hook either. Regular sodas, sweetened teas and energy drinks remain one of the most well-documented contributors to rising diabetes and obesity rates worldwide. Even 100% fruit juices, which many perceive as healthy, can elevate blood sugar when consumed in excess. This new study challenges the widely accepted belief that diet drinks are a safe swap. And while more research is needed to pinpoint exactly how artificial sweeteners may influence insulin response, the evidence so far suggests that moderation—and even reconsideration—is warranted. So, what should you drink instead? Nutrition experts continue to recommend simple, no-frills hydration. Water remains the gold standard, but unsweetened tea and black coffee are also considered safe and beneficial for most people. Infused waters with fruit or herbs can offer a flavorful twist without the potential downsides of sugar or artificial sweeteners. I'm a daily Coke Zero drinker, but after this study, I may be willing to make a change. I do love iced tea!Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes first appeared on Parade on Jun 27, 2025 This story was originally reported by Parade on Jun 27, 2025, where it first appeared.

AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment

Yahoo

time35 minutes ago

  • Yahoo

AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the 'Elahere Market Opportunities and Strategies to 2034' report was added to offering. It stated that the global market for Elahere, which is a treatment primarily for ovarian cancer, is anticipated to experience rapid growth and is projected to surge from nearly $502.56 million in 2024 to $6.07 billion by 2034 at a CAGR of 28.68% from 2029. AbbVie, through its acquisition of ImmunoGen, is currently the sole and dominant player in the Elahere market, holding a 100% market share in 2023. AbbVie completed its acquisition of ImmunoGen on February 12 in 2024, in a deal that was valued at ~$10.1 billion. The acquisition was made to support AbbVie's oncology pipeline, particularly with Elahere. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. Elahere is indicated for ovarian neoplasms, which constituted the largest segment by clinical indication and accounted for 85.44% or $429.38 million of the market in 2024. This segment is expected to remain the fastest-growing with a CAGR of 29.67% during the 2024-2029 period. North America was the largest regional market for Elahere in 2024, and accounted for 97.09% of the total, or $487.92 million. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues

Yahoo

timean hour ago

  • Yahoo

Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, Wegovy. This decision was made less than two months after the companies had initially announced their collaboration. A healthcare professional holding a device with innovative technology developed by the medical technology company. According to Novo Nordisk, Hims & Hers failed to adhere to the law prohibiting mass sales of compounded drugs under the 'false guise of 'personalization'.' The company accused its partner of disseminating 'deceptive marketing' that risks patient safety and selling 'illegitimate, knockoff versions' of Wegovy. Novo Nordisk states that its investigation showed the active pharmaceutical ingredients (APIs) in these knockoff drugs, particularly 'semaglutide' from telehealth entities and compounding pharmacies, are manufactured by foreign suppliers in China and were often not inspected by the FDA. In response, Andrew Dudum, CEO of Hims & Hers, stated on X that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum alleged that Novo Nordisk's commercial team 'increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.' He asserted that Hims & Hers 'refuse[s] to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.' Novo Nordisk A/S (NYSE: NVO) is a Danish healthcare company operating globally. It develops, manufactures, and markets pharmaceutical products for the treatment of chronic diseases, primarily diabetes and obesity. Its well-known products include Ozempic, Wegovy, Rybelsus, and Norditropin. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store